HOME > About Walvax > Product

23-valent Pneumococcal Polysaccharide Vaccine

  23-valent Pneumococcal Polysaccharide Vaccine is a product developed independently by Yunan Walvax. It obtained the Drug Registration Approval from China Food and Drug Administration on March, 2017 (No.: 2017S00156, Drug Approval No.: Guoyao Zhunzi S20170003), and it was launched to the market in July 2017.  

  This vaccine is produced by culture, extraction and purification of polysaccharide antigens of 23 epidemic and infectious Streptococcus pneumoniae serotypes, namely 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. It is a clear and colorless solution free of preservative. It is recommended for children over 2 years of age who are at increased risk for pneumococcal disease. The vaccine can induce immune response in recipients following immunization. It is used for the prevention of pneumococcal disease caused by the 23 serotypes above.